Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Corneal News
Q2-2025 Ophthalmic Revenue Roundup for Roche, Bausch + Lomb, Apellis, Glaukos, and Astellas
Swiss company Roche reported July 24 that Vabysmo sales for Q2-2025 were CHF 1.05 billion ($1.3 billion, converted June 30, 2025), a 19 percent increase over CHF 947 million in Q2-2024. Roche said ...
EyeDura Wins Two Octane Awards for Sustained-Release Eye Drop Platform
EyeDura Therapeutics earned the judges’ top award during Octane’s capital and growth company presentations, which spotlighted early-stage, high-potential ophthalmic ventures. The company was a favo...
Clinical Trial Updates for Ophthalmic Candidates, July 2025
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
PDUFA Dates for Ophthalmic Drug Candidates, July 2025
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
EyeDura and its Eye Drop Platform Continue to Win Honors from Accelerators
EyeDura Therapeutics reported July 15 that the company had earned the Judges’ Choice and People’s Choice awards at the Octane Ophthalmology Tech Forum, held June 27 in Newport Beach, California. Th...
Spain’s Faes Farma Acquires Italy’s SIFI in Deal Worth $310.4 Million
Faes Farma, of Bilbao, Spain, announced June 11 that it had signed an agreement to acquire 100 percent of Italian ophthalmic company SIFI. The deal values SIFI at €270 million (US $310.4 million, c...
Emerging Companies Pursuing Ophthalmic Indications, June 2025
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
PDUFA Dates for Ophthalmic Drug Candidates, June 2025
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
Spain’s Faes Farma Acquires Italy’s SIFI in Deal Worth $310.4 Million
Faes Farma, of Bilbao, Spain, announced June 11 that it had signed an agreement to acquire 100 percent of Italian ophthalmic company SIFI. The deal values SIFI at €270 million (US $310.4 million, c...
Allotex Launches Refractive Corneal Implant in Canada
Allotex announced May 22 the approval and launch in Canada of Transform, its human collagen-based corneal implant for vision correction. The company said it had partnered with Clarion Medical Techn...
SIFI Gains Marketing Authorization, PIM Designation for Akantior Drops in UK
Italy’s SIFI reported May 19 that it had gained marketing authorization from the UK’s Medicines and Healthcare Products Regulatory Agency for Akantior eye drops for the treatment of Acanthamoeba ke...
Clinical Trial Updates for Ophthalmic Candidates, May 2025
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Emerging Companies Pursuing Ophthalmic Indications, May 2025
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
May 2025 Ophthalmic News Briefs
London’s Okyo Pharma announced April 30 that it would accelerate development of topical urcosimod, formerly OK-101, in neuropathic corneal pain, following early closure of its Phase II trial. The t...
Okyo Pharma Accelerates Development of Urcosimod in Neuropathic Corneal Pain
London’s Okyo Pharma announced April 30 that it would accelerate development of urcosimod, formerly OK-101, in neuropathic corneal pain, following early closure of its Phase II trial. The trial was...
Q1-2025 Ophthalmic Revenue Roundup for Roche, Regeneron, AbbVie, Glaukos, Lumibird, and Biogen
Swiss company Roche reported April 24 that Vabysmo sales in Q1-2025 were CHF 1 billion ($1.1 billion, calculated March 31, 2025), up 18 percent in constant currency from CHF 847 million in Q1-2024....
Aurion Biotech Appoints Edward J. Holland, MD, as Chief Medical Officer
Aurion Biotech announced April 23 that it had appointed Edward J. Holland, MD, as chief medical officer. Aurion’s lead asset is AURN001, being developed for corneal edema secondary to corneal endot...
Design Therapeutics Appoints Chris M. Storgard, MD, as Chief Medical Officer
Design Therapeutics announced April 17 that it had appointed Chris M. Storgard, MD, as chief medical officer (CMO). The Carlsbad, California, company is developing DT-168, a small molecule targetin...
Veo Launches Plexitome to Treat Recurrent Corneal Erosion, Corneal Abrasions
Veo Ophthalmics, of Chester, Ohio, announced April 14 that it had launched its Plexitome surgical instrument for the treatment of recurrent corneal erosion and large corneal abrasions. The FDA-regi...
Senju Licenses Brill’s Non-contact Esthesiometer for Japan
Japanese company Senju Pharmaceutical reported March 7 that it had licensed Brill International’s corneal esthesiometer for use in Japan. Senju said the device mainly had been distributed by Brill ...
Alcon Announces Majority Ownership of Aurion Cell Therapy Company
Alcon announced March 26 that it had acquired a majority interest in Aurion Biotech, developer of a corneal cell therapy. News of Alcon’s majority stake—after acquiring additional shares in Aurion ...
April 2025 Ophthalmic News Briefs
Carl Zeiss Meditec announced March 21 the availability in Canada of the Visulas Combi, a green and YAG ophthalmic laser workstation combining photodisruption, photocoagulation, and slit lamp techno...
ACRO Biomedical Gains Regulatory Approval in Taiwan for Corneal Xenograft
Taiwan’s ACRO Biomedical announced April 13 that the country’s Ministry of Health and Welfare had granted regulatory approval to ACRO’s ABCcolla decellularized porcine collagen corneal xenograft. A...
Alcon Announces Majority Ownership of Aurion
Alcon announced March 26 that it had acquired a majority interest in Aurion Biotech, developer of a corneal cell therapy. News of Alcon’s majority stake—after acquiring additional shares in Aurion ...
Surrozen to Focus on Ophthalmic Pipeline, Raises up to $175 Million in Private Placement
Surrozen announced March 24 that it would focus on its ophthalmic pipeline, including the development of new treatment options for retinopathies. Concurrently, the company said that a private place...
Pantheon, Eyedeal Medical to Collaborate on Bioengineered Corneal Implant
Pantheon Vision announced March 27 that it would collaborate with Chinese ophthalmic device manufacturer Eyedeal Medical to advance the production and commercialization of Pantheon’s corneal implan...
Bausch + Lomb Launches Arise Orthokeratology Lens Fitting System in the US
Bausch + Lomb announced March 17 the US launch of Arise, a lens fitting system that uses cloud-based technology to streamline the orthokeratology lens design process. Orthokeratology (ortho-k) lens...
SIFI to Supply Akantior Drops for Investigator-Led Acanthamoeba Keratitis Trial
Italy’s SIFI announced March 18 that it will collaborate with the University of California, San Francisco (UCSF), in an investigator-led trial of patients with Acanthamoeba keratitis, a parasitic i...
PDUFA Dates for Ophthalmic Drug Candidates
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
US FDA Accepts NDA for Glaukos’ Epioxa for Epi-On Crosslinking Therapy
Glaukos, of Aliso Viejo, California, reported Feb. 24 that the US FDA had accepted its new drug application for Epioxa, an epi-on version of the company’s iLink corneal crosslinking therapy, for th...
Deerfield Sues Alcon over Latest Moves to Prevent Aurion IPO
Deerfield Management has filed a lawsuit against an Alcon subsidiary, seeking to prevent Alcon from interfering with Aurion Biotech’s ability to launch an initial public offering. The lawsuit, file...
Study of Corneal Stem Cell Transplant Shows Vision Restored After Injury
A clinical study of patients with irreversible corneal injury, published March 4 in Nature Communications, showed that transplanted epithelial stem cells from their healthy eyes restored at least p...
Study of Corneal Stem Cell Transplant Shows Vision Restored After Blinding Eye Injuries
A clinical study of patients with irreversible corneal injury, published March 4 in Nature Communications, showed that transplanted epithelial stem cells from their healthy eyes restored at least p...
Deerfield Sues Alcon over Latest Moves to Prevent Aurion IPO
Deerfield Management has filed a lawsuit against an Alcon subsidiary, seeking to prevent Alcon from interfering with Aurion Biotech’s ability to launch an initial public offering. The lawsuit, file...
US FDA Accepts NDA for Glaukos’ Epioxa, Sets PDUFA Date of Oct. 20, 2025
Glaukos, of Aliso Viejo, California, reported Feb. 24 that the US FDA had accepted its new drug application for Epioxa, an epi-on version of the company’s iLink corneal crosslinking therapy, for th...
February 2025 Ophthalmic News Briefs
Outlook Therapeutics reported Jan. 16 the final results of the NORSE EIGHT trial of ONS-5010 (Lytenava), an ophthalmic formulation of bevacizumab for wet AMD. ONS-5010 demonstrated non-inferiority ...
Kala Bio’s CEO Resigns; President, COO Takes Over as Interim
Kala Bio announced Feb. 12 that its chief executive officer, Mark Iwicki, had resigned, and that Todd Bazemore, Kala’s president and chief operating officer, had been appointed interim CEO, effecti...
Aurion Plans to Launch IPO; Alcon Loses Court Bid to Stop Move
A judge will allow Aurion Biotech, of Seattle, Washington, to go ahead with its planned initial public offering after rejecting shareholder Alcon’s arguments to prevent the move. The decision was h...
Glaukos Submits NDA for Epioxa Epi-On Crosslinking Treatment
Glaukos, of Aliso Viejo, California, reported Dec. 23 that it had submitted its new drug application to the US FDA for Epioxa, an epi-on version of the company’s iLink corneal crosslinking therapy,...
Aviceda Leads Latest Ophthalmic Fundraising with $207.5 Million Round
Aviceda Therapeutics led recent ophthalmic fundraising efforts with an upsized $207.5 million Series C financing round to support its trials in geographic atrophy. Financing announced in the past f...
Clinical Trial Updates for Ophthalmic Candidates, January 2025
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Carter’s Many Accomplishments Include Saving Millions from Blindness
Former US president Jimmy Carter’s many legacies include saving the of sight of millions of people in less developed regions by providing treatment for onchocerciasis and trachoma through his Carte...
Emerging Companies Pursuing Ophthalmic Indications, January 2025
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
January 2025 Ophthalmic News Briefs
China’s Eyebright Medical announced Jan. 7 that its phakic intraocular lens, the Loong Crystal PR, had received certification as a Class III medical device from the country’s National Medical Produ...
SightStream is Developing an Eye Drop Candidate for Corneal Endothelial Disease
SightStream Biotherapeutics, an ophthalmic drug development company spun out of Harvard University in 2020, is raising $7.5 million in Series A funding to advance its preclinical melanocortin recep...
Carter’s Many Accomplishments Include Saving Millions from Blindness
Former US president Jimmy Carter’s many legacies include saving the of sight of millions of people in less developed regions by providing treatment for onchocerciasis and trachoma through his Carte...
Glaukos Submits NDA for Epioxa Epi-On Crosslinking Treatment
Glaukos, of Aliso Viejo, California, reported Dec. 23 that it had submitted its new drug application to the US FDA for Epioxa, an epi-on version of the company’s iLink corneal crosslinking therapy,...
Provectus Launches VisiRose to Commercialize Rose Bengal Antimicrobial Light Treatments
Provectus Biopharmaceuticalsannounced Dec. 11 that it had launched VisiRose, a company focused on commercializing rose bengal photodynamic antimicrobial therapy (PDAT) for infectious keratitis and ...
SIFI Files for UK Approval of Akantior Drops for Acanthamoeba Keratitis
Italy’s SIFI reported Dec. 16 that it had filed a marketing authorization application with the UK’s Medicines and Healthcare Products Regulatory Agency for Akantior (polihexanide 0.08%) drops for t...
Clinical Trial Updates for Ophthalmic Candidates, December 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Cornea Transplant Market Continues to Face Procurement Challenges, as New Approaches on Rise
An estimated 1 million corneas are needed each year to meet the demand of those who could benefit from a transplant. Several factors contribute to the global shortage of corneal tissue. In many cou...
Cornea and Eye Banking Forum Looks at Ways to Expand the Donor Pool
Expanding the donor pool was once again top of mind at the 2024 Cornea and Eye Banking Forum, held Oct. 18 in conjunction with the AAO meeting in Chicago, Illinois. The forum, supported by the Eye ...
Clinical Trial Updates for Ophthalmic Candidates, November 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis, Glaukos, STAAR, and Lensar
AbbVie, of North Chicago, Illinois, reported Oct. 30 that its Q3-2024 eye care net revenue was $525 million, a 13.5 percent decline (-11.2 percent cc) from $605 million in Q3-2023. Restasis revenue...
Grifols, BARDA Partner on Ocular Immunoglobulin Drops for Sulfur Mustard Exposure
Barcelona-basedGrifols reported Oct. 22 that it is partnering with the US government’s BARDA to test ocular surface immunoglobulin (OSIG) eye drops for their ability to treat ocular damage from sul...
Cure Blindness Project Expands Sight-Saving Care to Six New Countries
Cure Blindness Project is expanding to six new countries—Burundi, Democratic Republic of the Congo, Liberia, Pakistan, Paraguay, and Zambia, the charity reported Oct. 10. Paraguay marksthe charity’...
Select US FDA Approvals and Clearances in September 2024
The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in September 2024, according to the agency’s database. Zeiss gained clearance for its combination Y...
Aurion Biotech Launches Vyznova Corneal Cell Therapy in Japan
Aurion Biotech announced Sept. 24 that it had launched Vyznova (neltependocel), a cell therapy for bullous keratopathy of the cornea, in Japan. Japanese regulators approved Vyznova in March 2023. T...
Cornea Surgeons Examine New Crosslinking Options and Old Debates
Farhad Hafezi, MD, PhD, FARVO (Switzerland), discussed at the 2024 ESCRS congress the goals of the second global consensus on keratoconus, being drafted in 2024. This consensus encompasses feedback...
Clinical Trial Updates for Ophthalmic Candidates, October 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
SIFI Launches Akantior Drops for Acanthamoeba Keratitis in Germany
Italy’s SIFI announced Sept. 30 the launch in Germany of its Akantior (polihexanide 0.08%) drops for the treatment of Acanthamoeba keratitis (AK), a parasitic infection of the eye, in patients 12 a...
Aurion Launches Vyznova Corneal Cell Therapy in Japan
Aurion Biotech announced Sept. 24 that it had launched Vyznova (neltependocel), a cell therapy for bullous keratopathy of the cornea, in Japan. Japanese regulators approved Vyznova in March 2023. T...
European Commission Approves SIFI’s Akantior Drops for Acanthamoeba Keratitis
Italy’s SIFI announced Aug. 26 that the European Commission had approved Akantior (polihexanide 0.08%) drops for the treatment of Acanthamoeba keratitis (AK), a parasitic infection of the eye, in p...
Emerging Companies Pursuing Ophthalmic Indications, August 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Renowned Charity HCP Cureblindness Rebrands as Cure Blindness Project
HCP Cureblindness has rebranded as the Cure Blindness Project, the group announced July 29. The move is designed to better reflect the eye charity’s expanded geographical footprint and commitment t...
August 2024 Ophthalmic News Briefs
Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application for t...
Santen Licenses Cloudbreak Topical Pterygium Candidate for Japan, Korea, and Southeast Asia
Japan’s Santen announced Aug. 6 that it had signed an agreement to license CBT-001, a topical pterygiumtreatment candidate from Cloudbreak Pharma. The deal covers the territories of Japan, South Ko...
Mallinckrodt Announces Availability of Acthar Gel SelfJect Injector in the US
Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application (sNDA...
HCP Cureblindness Rebrands as Cure Blindness Project
HCP Cureblindness has rebranded as the Cure Blindness Project, the group announced July 29. The move is designed to better reflect the eye charity’s expanded geographical footprint and commitment t...
Q2-2024 Ophthalmic Revenue Roundup for Regeneron, Roche, Bausch + Lomb, Novartis, and Four Others
Regeneron, of Tarrytown, New York, reported Aug. 1 that its Q2-2024 US revenue for Eylea was $1.53 billion, a 2 percent increase from $1.5 billion in Q2-2023. Eylea HD accounted for $304 million of...
Bausch + Lomb Acquires Dry Eye Diagnostic Company Trukera Medical
Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...
Eyenovia, Senju Will Collaborate on Chronic Dry Eye Candidate with Optejet Microdoser
Eyenovia, of New York, announced July 23 that it had entered into a collaboration agreement with Japan’s Senju Pharmaceutical to develop Senju’s corneal epithelial wound healing candidate, SJP-0035...
Advisory Panel Recommends Orphan Drug Status for SIFI’s Polihexanide in Fungal Keratitis
Italy’s SIFI announced July 22 that a European advisory panel had recommended orphan drug designation for its polihexanide eye drop for fungal keratitis. The Committee for Orphan Medicinal Products...
Beacon Leads Latest Ophthalmic Fundraising with $170 Million in Series B
Beacon Therapeutics led recent ophthalmic fundraising efforts with $170 million in Series B funding to advance its candidates for retinal disease. Financing announced in the past four weeks totaled...
Claes H. Dohlman, MD, PhD, Corneal Research Pioneer and Inventor of the Boston KPro, Dies at 101
Claes H. Dohlman, MD, PhD, considered by many to be the father of modern corneal science, died July 14, Massachusetts Eye and Ear announced in a press release. He was 101. Dohlman, who was born in ...
July 2024 Ophthalmic News Briefs
Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...
Claes H. Dohlman, MD, PhD, Corneal Research Pioneer and Inventor of the Boston KPro, Dies at 101
Claes H. Dohlman, MD, PhD, considered by many to be the father of modern corneal science, died July 14, Massachusetts Eye and Ear announced in a press release. He was 101. Dohlman, who was born in ...
Okyo Pharma to Initiate Phase II Trial for OK-101 in Neuropathic Corneal Pain
London’s Okyo Pharma announced July 11 that it would advance OK-101 into a Phase II clinical trial of neuropathic corneal pain (NCP). The US FDA cleared the investigational new drug (IND) applicati...
J&J Leads Series A Round for Crosslinking Tech Developer TecLens
Johnson & Johnson is the lead investor in a Series A funding round for Stamford, Connecticut-based TecLens, developer of a new crosslinking technology, J&J announced June 21. The technology is inte...
US FDA Grants Breakthrough, Regenerative Medicine Status to Aurion’s Corneal Cell Therapy Candidate
Aurion Biotech announced June 19 that the US FDA had granted both breakthrough therapy and regenerative medicine advanced therapy status for AURN001, the company’s allogeneic cell therapy candidate...
Eye Banking Meeting Celebrates Successful Transplants, Looks at Needs Going Forward
Attendees at the 2024 Eye Banking Association of America (EBAA) meeting celebrated many achievements and milestones across the eye banking profession and transplant community in general, as 2023 ma...
SIFI’s Acanthamoeba Keratitis Eye Drop Candidate Gains Positive CHMP Opinion
Italy’s SIFI announced May 31 that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended approval of Akantior (polihexanide 0.08%) for the treatment...
Eversight Partners with LighTopTech to Improve Imaging of Eye Tissues
Global nonprofit eye bank Eversight announced June 5 a four-year partnership with LighTopTech to improve imaging for eye tissues in clinical and research settings. Eversight will integrate LighTopT...
BioTissue Introduces Shelf-Stable CAM360 AmnioGraft for Dry Eye, Other Disorders
BioTissue announced June 3 that it was launching the CAM360 AmnioGraft, a new hydrated, shelf-stable cryopreserved amniotic membrane product for mild to moderate dry eye and other ocular surface di...
Eversight Partners with LighTopTech to Improve Imaging of Eye Tissues
Global nonprofit eye bank Eversight announced June 5 a four-year partnership with LighTopTech to improve imaging for eye tissues in clinical and research settings. Eversight will integrate LighTopT...
BioTissue Introduces Shelf-Stable CAM360 AmnioGraft for Dry Eye, Other Disorders
BioTissue announced June 3 that it was launching the CAM360 AmnioGraft, a new hydrated, shelf-stable cryopreserved amniotic membrane product for mild to moderate dry eye and other ocular surface di...
Acanthamoeba Keratitis Eye Drop Candidate from SIFI Gains Positive CHMP Opinion
Italy’s SIFI announced May 31 that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended approval of Akantior (polihexanide 0.08%) for the treatment...
Emerging Companies Pursuing Ophthalmic Indications, May 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
2024 ARVO Awards Highlight New Focus on Inflammation
The Weisenfeld and Cogan awards and lectures at the 2024 ARVO meeting put a spotlight on inflammation. Martine Jager, MD, PhD (Netherlands), received the Weisenfeld Award in recognition of her pion...
Clinical Trial Updates for Ophthalmic Candidates, May 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
May 2024 Ophthalmic News Briefs
Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...
Bausch + Lomb Launches Zenlens Echo Scleral Lenses in the US
Bausch + Lomb announced May 7 that it had launched the Zenlens Echo, a non-prosthetic, custom scleral contact lens, in the US. The company said the Echo is designed to fit a wide variety of corneal...
Outlook Leads Latest Ophthalmic Fundraising with $164M in Private Placements
Retinal drug developer Outlook Therapeutics led recent ophthalmic fundraising efforts with two private placements, for proceeds totaling $164 million. Financing announced in the past four weeks tot...
Rise of DMEK Highlights Need for Corneal Endothelial Therapies
Descemet’s membrane endothelial keratoplasty (DMEK) has become the most common keratoplasty procedure performed domestically, according to a statistical report by the Eye Bank Association of Americ...
Emerging Companies Pursuing Ophthalmic Indications, April 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Clinical Trial Updates for Ophthalmic Candidates , April 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
April 2024 Ophthalmic News Briefs
Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis opt...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.